A detailed history of Capital Group Private Client Services, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Capital Group Private Client Services, Inc. holds 110,895 shares of REGN stock, worth $75.9 Million. This represents 1.17% of its overall portfolio holdings.

Number of Shares
110,895
Previous 100,228 10.64%
Holding current value
$75.9 Million
Previous $105 Million 10.67%
% of portfolio
1.17%
Previous 1.1%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1024.09 - $1201.76 $10.9 Million - $12.8 Million
10,667 Added 10.64%
110,895 $117 Million
Q2 2024

Aug 13, 2024

SELL
$883.2 - $1071.19 $3.22 Million - $3.9 Million
-3,641 Reduced 3.51%
100,228 $105 Million
Q1 2024

May 14, 2024

BUY
$902.69 - $993.35 $9.8 Million - $10.8 Million
10,857 Added 11.67%
103,869 $100 Million
Q4 2023

Feb 13, 2024

BUY
$775.18 - $881.7 $260,460 - $296,251
336 Added 0.36%
93,012 $81.7 Million
Q3 2023

Nov 13, 2023

BUY
$692.45 - $844.37 $18.1 Million - $22 Million
26,108 Added 39.22%
92,676 $76.3 Million
Q2 2023

Aug 11, 2023

BUY
$700.03 - $830.35 $29.1 Million - $34.6 Million
41,630 Added 166.93%
66,568 $47.8 Million
Q1 2023

May 15, 2023

BUY
$680.49 - $826.97 $1.39 Million - $1.69 Million
2,048 Added 8.95%
24,938 $20.5 Million
Q4 2022

Feb 14, 2023

BUY
$705.89 - $766.39 $42,353 - $45,983
60 Added 0.26%
22,890 $16.5 Million
Q3 2022

Nov 14, 2022

BUY
$573.97 - $724.32 $47,065 - $59,394
82 Added 0.36%
22,830 $15.7 Million
Q2 2022

Aug 15, 2022

SELL
$548.35 - $738.84 $24,127 - $32,508
-44 Reduced 0.19%
22,748 $13.4 Million
Q1 2022

May 16, 2022

BUY
$595.12 - $698.43 $13.6 Million - $15.9 Million
22,792 New
22,792 $15.9 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $73.4B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Capital Group Private Client Services, Inc. Portfolio

Follow Capital Group Private Client Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Group Private Client Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital Group Private Client Services, Inc. with notifications on news.